FDA 483 - Richard Dumas - March 29, 2018

Richard Dumas, a clinical investigator in Laval, was inspected by the FDA and cited for significant deficiencies in clinical trial conduct. The inspection revealed failures in obtaining legally effective informed consent, not conducting investigations according to the protocol, and inadequate maintenance of case histories. These issues primarily affected the CANVAS and CANVAS-R clinical studies.